The current status of T-cell depleted allogeneic stem-cell transplant in adult patients with AML

Cytotherapy

Volumn 3, Issue 3, 2001, Pages 175-188

  Bunjes, D ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIGEN; ANTINEOPLASTIC AGENT; BUSULFAN; CAMPATH 1 IMMUNOGLOBULIN G; CAMPATH 1 IMMUNOGLOBULIN M; CD33 ANTIGEN; CD45 ANTIGEN; CD52 ANTIGEN; CD66 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DIMETHYLBUSULFAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HLA ANTIGEN; INTERLEUKIN 2; IODINE 131; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 MONOCLONAL ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; RHENIUM 188; RITUXIMAB; STEROID; THIOTEPA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD DONOR; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DONOR; DRUG EFFICACY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VIVO STUDY; PATHOGENESIS; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RADIATION; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; VIRUS INFECTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOTRANSPLANTATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; METHODOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; GRAFT VS HOST DISEASE; HUMAN; IMMUNOSUPPRESSION; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOPROLIFERATIVE DISORDERS; RECURRENCE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 0034754525     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532401753174007     Document Type: Review

References (186)

1. Intensive postremission chemotherapy in adults with acute myeloid leukemia
2. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
3. Allogeneic hematopoietic stem cell transplantation for acute leukemia
4. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia
5. Chemotherapy v marrow transplantation for adults with nonlymphoblastic leukemia: A five-year follow-up
6. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia
7. Autologous or allogeneic bone marrow transplantation compared with chemotherapy in acute myelogenous leukemia
8. Results of allogeneic stem cell transplantation for malignant disorders
9. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
10. Graft-versus-host disease
11. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia
12. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
13. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
14. Marrow transplantation from unrelated volunteer donors
15. Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience
16. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
17. Anti-lymphocyte antibodies and marrow transplantation. III. Effect of heterologous anti-brain antibodies in acute secondary disease in mice
18. Lethal graft-vs-host disease following bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T-cells from marrow
19. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells
20. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients
21. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody
22. Ex-vivo treatment of donor marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease
23. Ex vivo T-cell depletion with the monoclonal antibody CAMPATH-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation
24. Evaluation of HLA-haplotype dispararate parental marrow grafts depleted of T cells by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency
25. Successful engraftment of T-cell-depleted haploidentical three loci incompatible transplants in leukaemia patients by addition of recombinant human granulocyte colony-stimulating-factor mobilized peripheral blood progenitor cells to marrow inoculum
26. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants
27. Treatment of donor bone marrow with monoclonal anti T cell antibody and complement for the prevention of graft-versus-host disease: A prospective, randomized, double-blind trial
28. Bone marrow transplantation for patients with chronic myeloid leukaemia: T cell depletion with CAMPATH-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse
29. Immune reconstitution following bone marrow reconstitution: Comparison of recipients of T cell depleted marrow with recipients of conventional marrow grafts
30. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with haematological malignancies
31. T-cell depletion of HLA-identical transplants in leukemia
32. Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts
33. Graft failure after T cell-depleted bone marrow transplantation: Clinical and immunological characteristics and response to immunosuppressive therapy
34. Graft rejection by a population of primed CDw52- host T cells after in vivo/ex vivo T-depleted bone marrow transplantation
35. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukaemia
36. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants
37. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukaemia: II. In vivo analyses of host effector mechanisms
38. Bone marrow graft rejection by host-derived allocytotoxic T lymphocytes recognizes a single amino acid at position 156 of the HLA-B44 class I antigen
39. Multiple minor histocompatibility antigen-specific cytotoxic T cell clones can be generated during graft rejection after HLA-identical bone marrow transplantation
40. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens
41. CD8+/DR+/CD25-T-lymphocytes associated with marrow graft failure
42. Engraftment of T-cell depleted bone marrow in murine models for allogeneic bone marrow transplantation
43. Booster irradiation to the spleen following total body irradiation
44. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts
45. Enhancement of T cell-depleted bone marrow allografts by thiotepa
46. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors
47. Graft failure and leukaemia relapse following T lymphocyte-depleted bone marrow transplants: Effect of intensification of immunosuppressive conditioning
48. Prevention of graft-versus-host disease by ex vivo T cell depletion: Reduction in graft failure with augmented total body irradiation
49. New approaches for the prevention of rejection and graft-versus-host disease in clinical bone marrow transplantation
50. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using CAMPATH-1 antibodies and post transplant administration of donors peripheral blood lymphocytes for prevention of relapse
51. T-cell depletion by exposure to CAMPATH-1G in vitro prevents graft-versus-host disease
52. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukaemia
53. Prevention of graft failure by an anti-LFA1 monoclonal antibody in HLA-mismatched bone marrow transplantation
54. Failure of a CD 18/anti-LFA-1 monoclonal antibody infusion to prevent graft rejection in leukaemic patients receiving T-depleted allogeneic bone marrow transplantation
55. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo
56. Comparative analysis of in vivo T cell depletion with radiotherapy, combination chemotherapy, and the monoclonal antibody CAMPATH-1G, using limiting dilution methodology
57. T-cell-depleted allogeneic bone marrow transplantation as post-remission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
58. Improved outcome with T-cell depleted bone marrow transplantation for acute leukemia
59. In vivo / ex vivo T cell depletion reduces the morbidity of allogeneic transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: Comparison with cyclosporin/methotrexate
60. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
61. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) reduces infection-related mortality after allogeneic T-depleted bone marrow transplantation
62. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation
63. + cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized trial
64. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans
65. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft
66. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GvHD and conserve a graft-versus-leukemia effect
67. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
68. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation
69. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose
70. + cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies
71. + cell dose predicts survival, postransplant morbidity and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
72. + cells/kg be considered the minimum threshold?
73. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
74. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors
75. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome
76. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission
77. HLA nonidentical T cell depleted marrow transplants: A comparison of results in patients for leukaemia and severe combined immunodeficiency disease
78. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA-haplotype
79. Transplantation of megadoses of purified haploidentical stem cells
80. + selected cells in mismatched stem cell transplantation: A single centre experience of haploidentical peripheral blood stem cell transplantation
81. + stem cells induce potent specific reductions of host-anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture
82. Use of partially mismatched related donors extends access to allogeneic marrow transplant
83. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T cell-depletion
84. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia
85. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies
86. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission
87. Graft-versus-leukemia reactions after bone marrow transplantation
88. Identical-twin bone marrow transplants for leukemia
89. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes
90. + minor histocompatibility antigen-specific cytotoxic T lymphocytes
91. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones
92. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL
93. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR present in acute promyelocytic leukemia cells
94. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
95. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
96. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
97. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
98. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT
99. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first remission
100. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
101. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation
102. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
103. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
104. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
105. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission
106. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study
107. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Sociètè Francaise de Greffe de Moelle (SFGM)
108. 188 Re-labeled anti-CD66 (a,b,c,e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: Results of a phase I-II study
109. The use of radiolabelled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
110. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
111. Selective radiation of hematolymphoid tissue delivered by anti-CD 45 antibody
112. Targeted hematopoietic irradiation using 131-I-anti-CD45 antibody in patients with acute leukemia undergoing marrow transplantation
113. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide
114. Results of allogeneic bone marrow transplant following 131 I-M 195/Busulfan/Cyclophosphamide (Bu/Cy) in patients with advanced/refractory myeloid malignancies
115. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias
116. Phase I study of 131 I-anti CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
117. Current uses of monoclonal antibodies in the treatment of acute leukemia
118. Allogeneic blood and bone marrow stem cell transplantation in haematological malignant diseases: A randomized trial
119. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers
120. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation
121. Comparative outcome of T-cell-depleted and non T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusions
122. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia
123. Immunologic reconstitution following stem cell transplantation
124. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
125. The effect of T cell depletion with CAMPATH 1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia
126. Immune reconstitution after allogeneic marrow transplantation depleted of T cells
127. The influence of T cell depletion on recovery of T cell proliferation to herpes viruses and candida after allogeneic bone marrow transplantation
128. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts
129. Cytomegalovirus infection and disease after T cell depleted allogeneic bone marrow transplantation for malignant hematologic diseases
130. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies
131. High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow transplantation for hematological malignancies following T cell depletion and cyclosporine
132. T-cell regeneration after bone marrow transplantation: Differential CD45 isoform expression on thymic-derived versus thymic-independent progeny
133. Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy
134. T cell reconstitution after bone marrow transplantation in adult patients does not resemble T cell development in early life
135. +T-lymphocyte regeneration after intensive chemotherapy
136. Constraints on CD4 recovery postchemotherapy in adults: Thymic insufficiency and apoptotic decline in expanded peripheral CD4 cells
137. Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation
138. Recovery of immune reactivity after T-cell-depleted bone marrow depends on thymic activity
139. T-cell repertoire complexity after allogeneic bone marrow transplantation
140. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analysed by CDR3 size spectratyping
141. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic one marrow transplant and the effect of donor lymphocyte infusions on T cell repertoire
142. Thymic aging and T cell regeneration
143. Thymic function in young/old chimeras: Substantial thymic T cell regenerative capacity despite irreversible age-associated thymic involution
144. Direct evidence of thymic function in adult humans
145. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor
146. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones
147. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
148. Selective removal of alloreactive cells from haematopoietic stem cell grafts: Graft engineering for GVHD prophylaxis
149. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions
150. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
151. Transplantation of anergic histoincompatible bone marrow allografts
152. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation
153. Identification of target antigens for the human T-cell response to Epstein-Barr virus (EBV): Implications for the control of EBV-positive malignancies
154. Risk of lymphoproliferative disorders after bone marrow transplantation: A multiinstitutional study
155. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants
156. Prevention of EBV-induced B lymphoproliferative disorder by ex-vivo marrow B cell depletion in HLA-phenoidentical or nonidentical T-depleted bone marrow transplantation
157. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
158. Semiquantatative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
159. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
160. Humanized anti-CD 20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis of 32 patients
161. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
162. Donor T cells to treat EBV-associated lymphoma
163. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgastrim (granulocyte colony-stimulating factor)
164. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantages of blood over marrow allografts
165. Transplantation of allogeneic blood stem cells mobilized by recombinant human recombinant granulocyte colony-stimulating factor
166. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
167. Bone Marrow (BMT) versus lenogastrim-primed blood cell (BCT) allogeneic transplantation: A randomized trial from the Sociètè Francaise De Greffe de Moelle
168. + blood cells
169. + peripheral blood stem cells in patients with advanced hematologic malignancy
170. Allogeneic transplantation of positively selected peripheral blood progenitors from matched related donors
171. + selected cells from peripheral blood
172. Allogeneic transplantation of selected CD34+ cells from peripheral blood: Experience of 62 cases using immunoadsorption of immunomagnetic technique
173. + selected cells from peripheral blood of HLA-identical siblings
174. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
175. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
176. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
177. T-cell depleted allogeneic peripheral blood stem cell transplants in 30 patients with haematological malignancies: Benefits and risks
178. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
179. + cells derived from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells
180. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
181. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections
182. G-CSF blocks Il-12 production by antigen-presenting cells: Implications for improved immune reconstitution after haploidentical hematopoietic transplantation
183. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation
184. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning
185. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation